WuXi Biologics Buys Pfizer's Biologics Manufacturing Facility in Hangzhou

Shanghai 's WuXi Biologics, a global CDMO, will acquire a biotech drug manufacturing facility in Hangzhou from Pfizer China . Pfizer completed the facility in 2018 and was using it to manufacture biosimilar drugs. The deal will also include the facility's labor force. WuXi said the acquisition would boost its commercial drug substance (DS) and drug product (DP) capacity, meeting "surging" demand. The transaction is expected to close in the first half of 2021. Further financial details were not disclosed. More details.... Stock Symbol: (HK: 2269) Share this with colleagues: // //